VASOCONSTRICTOR ACTION OF ANGIOTENSIN-I CONVERTASE AND THE SYNTHETIC SUBSTRATE (PRO(11),D-ALA(12))-ANGIOTENSIN-I

被引:38
作者
MANGIAPANE, ML
RAUCH, AL
MACANDREW, JT
ELLERY, SS
HOOVER, KW
KNIGHT, DR
JOHNSON, HA
MAGEE, WP
CUSHING, DJ
BUCHHOLZ, RA
机构
关键词
ANGIOTENSINS; VASOCONSTRICTION; HEART; MAST CELLS; HYPERTENSION; ESSENTIAL;
D O I
10.1161/01.HYP.23.6.857
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
A chymase (also referred to as angiotensin I-convertase) specific for the conversion of angiotensin (Ang) I to Ang II has been identified in human heart. This serine protease is also present in dog and marmoset vasculature. We examined the vasoconstrictor effects of Ang II putatively generated from an angiotensin-converting enzyme (ACE)-resistant convertase synthetic substrate (SUB) in vivo and in vitro. In marmosets, SUB (7 to 700 mu g/kg IV) or Ang I (0.1 to 30 mu g/kg) caused similar dose-dependent increases in mean arterial pressure (10 to 100 mm Hg) and decreases in heart rate. Presser effects of SUB were slightly attenuated at low (but not high) doses by captopril (CAP, 1 mg/kg IV) and blocked by losartan (5 mg/kg IV); in contrast Ang I pressor effects were substantially blocked by bath. In isolated canine superior mesenteric artery, Ang I-induced contraction was eliminated by losartan and reduced but not eliminated by 10 mu mol/L CAP. When combined with the serine protease inhibitor chymostatin, CAP eliminated Ang I-induced contraction, but chymostatin alone had no effect. SUB-induced contraction was not blocked by CAP but was equally blocked by chymostatin (25 mu mol/L) alone or by the combination of CAP (10 mu mol/L) and chymostatin (25 mu mol/L); losartan (10 mu mol/L) eliminated SUB-induced responses. Previous studies have suggested that Ang I-convertase is important for production of Ang II in the heart. Our results are consistent with a potential role for Ang I-convertase in the production of Ang II in the vasculature, resulting in Ang II-mediated vasoconstriction.
引用
收藏
页码:857 / 860
页数:4
相关论文
共 12 条
[1]   ANTIHYPERTENSIVE THERAPY WITH MK-421 - ANGIOTENSIN-II-RENIN RELATIONSHIPS TO EVALUATE EFFICACY OF CONVERTING ENZYME BLOCKADE [J].
BIOLLAZ, J ;
BRUNNER, HR ;
GAVRAS, I ;
WAEBER, B ;
GAVRAS, H .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1982, 4 (06) :966-972
[2]  
HOIT BD, 1992, CIRCULATION, V86, P432
[3]  
HOOVER KW, 1993, FASEB J, V7, pA546
[4]   PLASMA ANGIOTENSINS AND BLOOD-PRESSURE DURING CONVERTING ENZYME-INHIBITION [J].
MENTO, PF ;
WILKES, BM .
HYPERTENSION, 1987, 9 (06) :42-48
[5]   DIFFERENT DISTRIBUTION OF 2 TYPES OF ANGIOTENSIN-II-GENERATING ENZYMES IN THE AORTIC-WALL [J].
OKUNISHI, H ;
MIYAZAKI, M ;
OKAMURA, T ;
TODA, N .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 149 (03) :1186-1192
[6]  
Okunishi H, 1984, J Hypertens, V2, P277
[7]   MARKED SPECIES-DIFFERENCE IN THE VASCULAR ANGIOTENSIN II-FORMING PATHWAYS - HUMANS VERSUS RODENTS [J].
OKUNISHI, H ;
OKA, Y ;
SHIOTA, N ;
KAWAMOTO, T ;
SONG, K ;
MIYAZAKI, M .
JAPANESE JOURNAL OF PHARMACOLOGY, 1993, 62 (02) :207-210
[8]   ACTIVATION OF 2 ANGIOTENSIN-GENERATING SYSTEMS IN THE BALLOON-INJURED ARTERY [J].
SHIOTA, N ;
OKUNISHI, H ;
FUKAMIZU, A ;
SAKONJO, H ;
KIKUMORI, M ;
NISHIMURA, T ;
NAKAGAWA, T ;
MURAKAMI, K ;
MIYAZAKI, M .
FEBS LETTERS, 1993, 323 (03) :239-242
[9]   REDOUBTABLE RESTENOSIS [J].
SMALLING, RW .
CIRCULATION, 1992, 86 (01) :325-327
[10]  
URATA H, 1990, J BIOL CHEM, V265, P22348